Cancer-Associated Fibroblasts, Lactate, and Chemoresistance: Insights into ANTXR1-Mediated Oxaliplatin Resistance in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) remains a leading cause of cancer mortality, accounting for approximately 9.3% of all cancer-related deaths worldwide. While oxaliplatin-based chemotherapy is a mainstay treatment for advanced and resected CRC, its effectiveness is often limited by the development of either primary or secondary drug resistance. Notably, up to 40% of CRC patients exhibit resistance to oxaliplatin, resulting in disease recurrence and metastasis despite initial therapy. The molecular mechanisms underlying this resistance are not fully elucidated, particularly the interplay between tumor cells and their microenvironment. Cancer stem cells (CSCs), well known for their self-renewal and chemoresistant properties, are maintained within supportive niches that include cancer-associated fibroblasts (CAFs). The reference study (Cancer Letters 631, 2025) addresses a pressing question: How do metabolic interactions between CAFs and CRC cells contribute to oxaliplatin resistance, and what are the underlying molecular mediators?

Key Innovation from the Reference Study

The central innovation of this research lies in identifying a novel mechanism by which CAF-derived lactate enhances oxaliplatin resistance in CRC through both transcriptional and post-translational regulation of the ANTXR1 protein. Specifically, the study demonstrates that lactate secreted by glycolytically active CAFs induces histone lactylation, promoting ANTXR1 gene transcription, and directly lactylates ANTXR1 at lysine 453 (K453la), thereby stabilizing the protein. This dual regulation of ANTXR1 facilitates activation of the RhoC/ROCK1/SMAD5 signaling pathway, ultimately promoting cancer stemness and chemoresistance. This mechanistic link between tumor-stromal metabolic crosstalk, protein lactylation, and drug resistance represents a significant advance over prior models that focused mainly on cell-intrinsic or genetic factors.

Methods and Experimental Design Insights

The study employed a multifaceted experimental design integrating molecular, cellular, and in vivo approaches:

• CAF Isolation and Characterization: CAFs were isolated from CRC patient tissue samples and characterized for glycolytic activity and lactate production.
• Co-culture Systems: CRC cell lines were co-cultured with CAFs or treated with exogenous lactate to model tumor-stromal interactions.
• Oxaliplatin Sensitivity Assays: Cell viability and apoptosis assays assessed the impact of CAF-derived lactate on oxaliplatin response.
• Histone and Protein Lactylation Analysis: Chromatin immunoprecipitation and immunoblotting evaluated lactylation of histones and ANTXR1 at specific residues.
• Gene Expression and Signaling Pathway Analysis: Quantitative PCR, immunofluorescence, and Western blotting were used to assess ANTXR1 levels and downstream pathway activation.
• In Vivo Models: Both cell-line and patient-derived xenograft (PDX) mouse models tested the functional consequences of modulating the lactate shuttle and ANTXR1 activity on chemoresistance.
• Genetic and Pharmacologic Inhibition: Targeted inhibitors and genetic knockdown approaches disrupted lactate transport or ANTXR1 expression to evaluate effects on drug sensitivity.

These complementary methods enabled the dissection of molecular mechanisms in both cell culture and physiologically relevant animal models, lending strong support to the study’s conclusions.

Core Findings and Why They Matter

• CAF-derived lactate confers oxaliplatin resistance: CRC cells exposed to CAF-conditioned medium or exogenous lactate exhibited reduced sensitivity to oxaliplatin-induced cytotoxicity (see study).
• Lactate induces ANTXR1 upregulation via histone lactylation: Increased levels of histone lactylation at the ANTXR1 promoter region were linked to enhanced transcriptional activity.
• ANTXR1 protein is stabilized by direct lactylation at K453: This post-translational modification prolongs ANTXR1 protein half-life, amplifying its cellular effects.
• ANTXR1 activates RhoC/ROCK1/SMAD5 signaling: This pathway is associated with maintenance of cancer stemness traits, as evidenced by upregulation of stem cell markers (LGR5, CD133, CD44) and sphere-formation assays.
• Disruption of lactate shuttling or ANTXR1 reverses resistance: Both genetic and pharmacological inhibition of lactate transporters or ANTXR1 restored oxaliplatin sensitivity in vitro and in xenograft models.
• Clinical correlation: Elevated ANTXR1 and ANTXR1 K453la levels in CRC patient samples were associated with poor prognosis and treatment outcomes.

Collectively, these findings delineate a new axis linking stromal metabolism, protein lactylation, and chemoresistance, highlighting potential intervention points for overcoming oxaliplatin resistance in CRC.

Comparison with Existing Internal Articles

While the reference study focuses on the tumor microenvironment and chemoresistance mechanisms in CRC, several internal articles discuss technical aspects of nucleic acid workflows critical for related experimental procedures. For example, "DNase I (RNase-free): Reliable DNA Removal for Robust Molecular Workflows" and "DNase I (RNase-free): Precision DNA Removal for RNA Workflows" detail best practices for eliminating DNA contamination in RNA-centric assays and RT-PCR, which are integral to gene expression and signaling pathway analyses like those performed in the current CRC study. These articles underscore the importance of using ribonuclease-free DNase I for DNA removal during RNA extraction, ensuring the purity and fidelity of downstream analyses such as qPCR and transcriptomic profiling. Such technical rigor is essential when quantifying gene expression changes (e.g., ANTXR1 upregulation) or validating pathway activation in cancer biology research.

Additionally, "DNase I (RNase-free): Precision Endonuclease for DNA Digestion" covers the enzyme's role in complex molecular biology workflows, including chromatin digestion and high-fidelity gene expression analysis—methods relevant to investigating histone modifications and protein-DNA interactions as seen in the CRC study.

Limitations and Transferability

Despite its significant advances, the study has several limitations:

• Model specificity: Although both cell-line and PDX models were used, patient-derived CAFs and tumor heterogeneity may differ in clinical populations.
• Long-term intervention effects: The durability and safety of lactate shuttle or ANTXR1 inhibition strategies were not assessed in long-term or immunocompetent models.
• Mechanistic scope: The study focused on a specific protein (ANTXR1) and pathway (RhoC/ROCK1/SMAD5), but other factors may also contribute to chemoresistance in vivo.

Nevertheless, the mechanistic insights are highly transferable to other research examining tumor-stroma metabolic crosstalk, protein modifications, and chemoresistance across cancer types.

Protocol Parameters

• CAF isolation and culture: Isolate primary CAFs from human CRC tissue, culture in DMEM with 10% FBS, verify glycolytic phenotype via lactate assays.
• Co-culture and treatment: Seed CRC cells with CAFs at a 1:1 ratio or supplement medium with 10–20 mM sodium lactate for 24–48 hours before oxaliplatin exposure.
• Histone/protein lactylation detection: Perform chromatin immunoprecipitation (ChIP) with anti-lactyl-lysine antibodies, followed by qPCR for ANTXR1 promoter analysis; use immunoblotting for K453la detection.
• Gene expression quantification: Extract total RNA using protocols incorporating ribonuclease-free DNase I to remove DNA contamination prior to RT-qPCR.
• In vivo studies: Inject luciferase-labeled CRC cells ± CAFs into immunodeficient mice, administer oxaliplatin (5–10 mg/kg) and/or metabolic inhibitors, monitor tumor growth and survival.

Research Support Resources

For researchers employing RNA extraction, gene expression assays, or chromatin studies similar to those in this CRC investigation, rigorous removal of DNA contamination is vital for data accuracy. DNase I (RNase-free) (SKU K1088) offers a reliable solution for DNA removal in RNA workflows, in vitro transcription sample preparation, and the analysis of chromatin modifications. This ribonuclease-free DNase I formulation is validated for both single- and double-stranded DNA digestion, supporting sensitive downstream applications as emphasized in recent molecular oncology and gene expression research. For detailed protocols and troubleshooting, readers may consult internal reviews of DNA removal and enzyme performance in advanced molecular workflows.